Chemoimmunotherapy with autologous NK‑cell therapy for children with refractory or relapsed high‑risk neuroblastoma and ganglioneuroblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 protocol enrolls pediatric patients with high‑risk neuroblastoma or ganglioneuroblastoma who have either a poor response to induction (refractory) or have relapsed/progressive disease. Patients undergo peripheral blood collection to grow an autologous NK‑cell product and then receive chemotherapy with irinotecan and temozolomide, combined with dinutuximab beta and infusions of the expanded NK cells on a defined schedule. Arm A (refractory) receives an intensified induction including one IT course followed by four DIT cycles with NK‑cell infusions on Day 7 of each DIT cycle; Arm B (relapsed/progressive) follows a similar plan after NK product manufacture. Cycles are given every 21 days and standard supportive care and follow‑up are provided per protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed voluntary informed consent to participate in the clinical trial
* Histologically verified diagnosis of neuroblastoma or ganglioneuroblastoma
* Patients stratified to the high-risk group according to the criteria of the German Society of Pediatric Oncology and Hematology (GPOH) - NB 2004, aged from 18 months to 18 years, and meeting the following conditions:

  1. Arm A: Refractory disease - patients who have completed the induction phase of therapy (6 cycles of N5/N6) with a poor response to therapy (MR, SD), with the exception of PD
  2. Arm В: Relapsed/progressive disease - patients who develop any new tumor lesions (after having previously achieved СR), or any new tumor lesion; an increase of \>25% in any previously existing measurable lesion; or newly detected bone marrow involvement by NB cells in cases where the bone marrow had previously been free of involvement
* Performance status ≥ 70% (Lansky or Karnofsky scale) at the time of determining the indication for chemoimmunotherapy combined with NK cell therapy.
* Expected life expectancy ≥ 12 weeks.
* No signs of drug-induced neuropathy or neuropathic pain.
* Adequate liver function: alanine aminotransferase (ALT) / aspartate aminotransferase (AST) activity \< 5 × upper limit of normal (ULN).
* Adequate renal function: creatinine clearance or glomerular filtration rate (GFR) \> 60 mL/min/1.73 m².
* Coagulation parameters: prothrombin index (PTI) 70-120%; activated partial thromboplastin time (APTT) \< 36 seconds.
* No clinical signs of heart failure; left ventricular ejection fraction (LVEF) ≥ 55%.
* Adequate respiratory function (oxygen saturation by pulse oximetry \> 94% on room air, no dyspnea at rest), and no pathological findings on chest X-ray.
* Completion of comprehensive assessment to evaluate the extent of the tumor process.

Exclusion Criteria:

* Lack of a signed voluntary informed consent form for participation in the clinical study.
* Absence of comprehensive pre-treatment assessment results at the time of initiation of specific therapy.
* Patients with NBL or ganglioneuroblastoma stratified to low or intermediate-risk group
* Good response (PR, VGPR, CR) or PD at the end of the induction phase of therapy (applicable only to patients receiving therapy within the framework of the intensified induction phase).
* Progressive or relapsed disease with central nervous system involvement and/or leptomeningeal involvement.
* History of acute intolerance reactions to the main chemotherapeutic and immunobiological agents and supportive care drugs used in this clinical trial protocol.
* Presence of complications of the underlying disease and comorbidities that preclude treatment within this protocol, including severe type I hypersensitivity reactions in the medical history.
* Requirement for concomitant medications with known cross pharmacodynamic interactions with the drugs used in this clinical trial protocol.
* Presence of ultrasonographic signs of heart failure (LVEF ≤ 55%), clinical and laboratory signs of chronic kidney disease of stage ≥ III, or kidney injury of grade I, F or L according to the standardized RIFLE criteria for acute kidney injury (an acronym for "risk, injury, failure, loss, end-stage").
* Pregnancy, due to the high teratogenicity and toxicity of the drugs used in this clinical trial protocol. Female patients of childbearing potential are required to undergo pregnancy testing.
* Mental illness of the patient or legal guardians that makes it impossible to understand the nature of the study and compromises adherence to medical prescriptions and sanitary-hygienic requirements.

Where it's running

• National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Tatyana V Shamanskay, MD, PHD
• Email: shamanskayatatyana@gmail.com
• Phone: 8 903 166-69-91

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted radiopharmaceutical radiotherapy for relapsed or refractory neuroblastoma

  A short, patient-friendly test of [211At]MABG radiotherapy to see if it is safe and tolerable in kids and young patients with relapsed or hard-to-treat neuroblastoma.

  Recruiting Early Phase 1 Sichuan University · Chengdu, Sichuan · NCT07767630

• Dual-target GD2 and B7-H3 CAR-NK therapy for children and young adults with relapsed or refractory neuroblastoma

  This trial tries an off-the-shelf CAR-NK cell treatment that targets GD2 and B7-H3 for children and young adults whose high-risk neuroblastoma has returned or not responded to prior therapy.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07502287

• Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for relapsed or refractory neuroblastoma in children

  This trial tests a four-drug combination to see if it can control neuroblastoma in children whose disease has come back or not responded to treatment.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07318831

• MIBG SPECT/CT and somatostatin receptor PET for diagnosing and staging neuroblastoma

  This study tests whether combining 123I‑MIBG SPECT/CT and somatostatin receptor PET improves detection, staging, and identification of PRRT candidates among children with suspected or confirmed neuroblastoma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07064746

• CAR-T cell therapy for relapsed neuroblastoma and desmoplastic small round cell tumors

  This study is testing a new CAR-T cell therapy to see if it can help people with relapsed neuroblastoma and desmoplastic small round cell tumors feel better and improve their chances of survival.

  Recruiting at 3 sites Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT06836505

• Using NK cells to treat high-risk neuroblastoma in children

  This study is testing if injections of special immune cells can help children aged 2 to 16 with tough-to-treat neuroblastoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Kian Immune Cell Company · Tehran · NCT06674265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.